Last
week, the Department of Health and Human Services delayed
implementation of its final rule on 340B drug ceiling prices and civil monetary
penalties for manufacturers until July 1, 2019. "With skyrocketing
prescription drug price increases presenting hospitals, health systems, and
patients with remarkable challenges, the 340B program is as critical as ever in
helping provide access to health care services for vulnerable patients and
communities," said American Hospital Association Executive Vice President
Tom Nickels. "The 340B ceiling price and civil monetary penalties rule
were intended to shine needed light on drug manufacturer price increases and
hold drug manufacturers accountable for price overcharging. These reasons are
why we continue to be disappointed in the delays—including five times since the
beginning of last year alone—of the final rule and in the short shrift given to
the review of the latest public comments. The irony is not lost on us that drug
manufacturers continue to lobby for increased reporting for hospitals and
others while refusing any transparency on their part."